Cue Biopharma (NASDAQ:CUE) Issues Earnings Results

Cue Biopharma (NASDAQ:CUE) posted its quarterly earnings results on Tuesday. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.36) by $0.02, MarketWatch Earnings reports. Cue Biopharma had a negative return on equity of 63.69% and a negative net margin of 1,142.70%.

Shares of Cue Biopharma stock opened at $12.70 on Friday. The firm has a market cap of $384.53 million, a P/E ratio of -8.09 and a beta of 1.95. Cue Biopharma has a fifty-two week low of $9.11 and a fifty-two week high of $31.69. The business has a 50-day moving average price of $13.53 and a 200 day moving average price of $19.96.

A number of research firms have issued reports on CUE. Oppenheimer reissued a “buy” rating and set a $32.00 price target on shares of Cue Biopharma in a research report on Tuesday, September 1st. BidaskClub downgraded Cue Biopharma from a “sell” rating to a “strong sell” rating in a research report on Wednesday, August 26th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the stock. Cue Biopharma currently has an average rating of “Hold” and an average target price of $31.00.

In other news, Director Cameron Gray acquired 5,000 shares of the stock in a transaction that occurred on Tuesday, September 29th. The stock was purchased at an average cost of $15.00 per share, with a total value of $75,000.00. Following the completion of the acquisition, the director now directly owns 672,500 shares in the company, valued at $10,087,500. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 9.50% of the stock is owned by insiders.

Cue Biopharma Company Profile

Cue Biopharma, Inc, a biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate CUE-101, a protein biologic that is in Phase I clinical trials designed to target and activate antigen-specific T cells for human papilloma virus driven cancers.

Read More: Which market index is the best?

Earnings History for Cue Biopharma (NASDAQ:CUE)

Receive News & Ratings for Cue Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cue Biopharma and related companies with's FREE daily email newsletter.